08:00 | Registration |
| High Content Assay Discovery |
| |
09:00 | | Keynote Presentation Novel Medicines for Unmet Medical Needs - Translational R&D in Singapore Alex Matter, CEO, Experimental Therapeutics Centre & D3 A*STAR, Singapore
ETC has assembled all the technologies that are needed to perform state-of-the-art drug discovery. The principle is to form a partnership with a premier academic group working on a set of well-defined, validated targets. The goal is to discover novel, attractive and feasible Preclinical Development Candidates.
Subsequently, a complementary facility (D3) will take up such projects and bring them through preclinical development that will enable to reach an IND (CTC).
Such a drug candidate can then enter early clinical trials, to reach a Proof-of-Concept (PoC) that is based on evidence of tolerability, plausible pharmacokinetics and biomarker evidence of attractive pharmacodynamics. |
|
10:00 | Target-mechanism based whole cell screen for mycobacterial proteome disruptors Thomas Dick, Associate Professor, National University of Singapore, Singapore
|
10:30 | Coffee Break and Networking in Exhibition Area |
11:15 | High Content Assays Measuring Human Brain Pericyte Biology Mike Dragunow, Professor of Pharmacology, Auckland University, New Zealand
Brain pericytes are perivascular cells thought to play diverse roles in brain physiology and pathology including regulating blood-brain barrier integrity and brain capillary function, and acting as neural stem cells. Pericytes have been implicated in BBB leakage, neuroinflammation and scar formation, suggesting that they are important targets for the development of CNS acting drugs. We have developed high content assays to measure various features of human brain pericytes for drug screening purposes to identify novel molecules regulating pericyte function. |
11:45 | Phenotypic Screening of Cellular Organelle Function Robin Ketteler, Group Leader/Manager, University College London, United Kingdom
I will present an overview of two phenotypic screens that study cell biology processes in a large-scale screening setup.
First, I will present our results on screening for modulators of autophagy comparing a luciferase-based and an image-based assay.
Next, I will discuss data from our high-content analysis of secretory granule function in endothelial cells. |
12:15 | Lunch Break and Poster Session |
13:45 | 3D Model Systems John Watson, Director, Promega Corporation, United States of America
|
| 3D Cellular Model Systems |
| |
14:15 | Scaffold- and Spheroid-based 3D Cell Culture Methods for Applications in Oncology and Toxicology Joy Hu, Technical Specialist, BioTek Instruments (Taiwan), Ltd., Taiwan
Automated methods for the preparation and execution of 3D cell culture methods using both scaffold- and spheroid-based methods will be presented.
Case studies in oncology and toxicology will be used as examples. |
14:45 | Coffee Break and Networking in Exhibition Area |
15:15 | Translational, robust 3D model systems for efficacy screening Jan Lichtenberg, CEO and Co-Founder, InSphero AG, Switzerland
Two key parameters assure high-quality screening data: valuable biological content and robust statistical relevance.
While three-dimensional (3D) cell models are widely recognized for their high level of organotypic morphology and functionality, well-to-well and batch-to-batch variations have been an obstacle in the past to translate this technology into standard screening processes.
In this presentation we illustrate how scaffold-free 3D microtissues obtained by an automated hanging-drop method yield highly uniform and organotypic cell models for screening in oncology and diabetes research. |
15:45 | Developing novel three dimensional cell culture platform for different testing purposes towards investigative biology Giridharan Periyasamy, Manager, Genome Institute of Singapore, Singapore
|
16:15 | Tour of the GIS High-throughput Cell Biology Centre (GIS-HTCB) |
17:30 | End of Day One |